REG - Biofrontera AG - Notice of Q3 Results <Origin Href="QuoteRef">B8FGn.DE</Origin>

Biofrontera AGAnnouncement

05/01/2016 13:29

RNS Number : 4750F
Biofrontera AG
12 November 2015
Biofrontera AG
Notice of Third Quarter Results 2015
Leverkusen, Germany, 12 November 2015 - Biofrontera AG (AIM: B8F), the biopharmaceutical company focusing on sun-induced skin cancer, will on 20 November 2015 announce its results for the nine months period ending 30 September 2015. 
A conference call for shareholders and interested investors will be held on 20 November 2015 at the following times:
3.00pm CET (2.00pm UK) conference call in German: 
Dial-in number: +49-(0)69-271340 166(room number not required)
4.30pm CET (3.30pm UK) conference call in English: 
Dial-in number Germany: +49-(0)69 271 340 801
Dial-in number UK: +44 203 36 45 807
Dial-in number USA: +1 240 64 50 345
Dial-in number USA (New York): +1 646 66 37 901
Conference code: 30057714#
Ends
Enquiries, please contact:
Biofrontera AG 
Thomas Schaffer, Chief Financial Officer
+49 (0) 214 87 63 2 0
press@biofrontera.com
www.biofrontera.com
IR Germany: Brainwell Asset Solutions 
Jrgen Benker
+49 (0) 152 08931514
Nomad and Broker: Shore Capital
Bidhi Bhoma / Toby Gibbs
+44(0) 20 7408 4090
IR UK: Seton Services
Toni Vallen 
+44(0) 20 7603 6797
Financial PR: Gable Communications
John Bick
+44(0) 20 7193 7463
+44 (0)7872 061007
Background:
The Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz, a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States. 
The company also markets the Belixos dermatological range of cosmetics. Belixos products, a cream, a gel and a scalp tonic, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. The Belixos Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All products are available through Amazon.
The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lbbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.
www.biofrontera.com
This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements. 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NORLIFFALRLFLIE